Financial Guidance - For the fiscal year ending December 31, 2025, research & development expenses are expected to be in the range of $55 million to $65 million[5] - Selling, general and administrative expenses are projected to be between $160 million and $170 million[5] - Total operating expenses are anticipated to be in the range of $215 million to $235 million[5] - The financial guidance reflects management's current expectations for the business[5] - The company presented this financial guidance at the 43rd Annual J.P. Morgan Healthcare Conference[5] Forward-Looking Statements - Forward-looking statements include expectations about full year expenses and financial performance[6] - Actual results may differ materially from the forward-looking statements due to estimates, assumptions, and uncertainties[6] - The company disclaims any obligation to update or revise forward-looking statements, except as required by law[6] Presentation and Reporting - Selected slides from the presentation are attached as Exhibit 99.1 to the Current Report[5] - The report was signed by Sheldon L. Koenig, President and CEO, on January 16, 2025[11]

Core Insights - Esperion reported a significant increase in total revenue for FY24, growing 186% year-over-year to $332.3 million, with U.S. net product revenue increasing 48% to $115.7 million [1][19] - The company is focusing on three strategic pillars: continued revenue growth, achieving operating profitability, and expanding its portfolio and pipeline [3][4] - Esperion is developing triple combination products with bempedoic acid in the U.S. to enhance treatment options for patients [1][8] Financial Performance - Q4 total revenue reached $69.1 million, a 114% increase year-over-year, while U.S. net product revenue grew 52% to $31.6 million [1][19] - Collaboration revenue surged 227% in Q4 and 470% for the full year, driven by increased royalty sales and product sales to collaboration partners [19] - The company reported a net loss of $21.3 million for Q4 and $51.7 million for the full year, a significant reduction from losses of $56.3 million and $209.2 million in 2023 [14][15] Market Expansion and Strategy - Esperion's products are now approved in 39 countries, enhancing access for patients with high LDL-C levels at risk of cardiovascular disease [4] - The company has expanded payer access, covering over 173 million lives across various insurance plans, and has seen a 12% increase in total retail prescription equivalents in Q4 [5][19] - Esperion is advancing its clinical pipeline and has initiated the development of two triple combination products, which may offer LDL-C lowering in excess of 60% [8][19] Research and Development - The company is committed to R&D, with a focus on acquiring synergistic cardiometabolic assets while advancing its clinical pipeline [8] - Esperion's R&D expenses decreased significantly in 2024, reflecting the close-out of the CLEAR Outcomes study [19] - The company plans to announce a lead indication for its next-generation inhibitors at an R&D Day in April 2025 [12] Financial Outlook - Esperion expects full-year 2025 operating expenses to be between $215 million and $235 million, including approximately $15 million in non-cash stock compensation expenses [17] - The company ended 2024 with cash and cash equivalents of $144.8 million, up from $82.2 million in 2023, indicating improved financial stability [15][33]

Core Insights - Esperion Therapeutics has entered into a license and distribution agreement with CSL Seqirus for the exclusive rights to commercialize NEXLETOL® and NEXLIZET® in Australia and New Zealand [1][4] - The partnership aims to address the significant burden of cardiovascular disease in these regions, where it affects 1.2 million people in Australia and 175,000 adults in New Zealand [2][3] Agreement Details - Under the agreement, Esperion will receive an upfront payment and milestone payments of up to approximately $5 million, and will supply finished products to CSL Seqirus at a profitable transfer price [5] - CSL Seqirus will handle the commercialization aspects, including regulatory approval, reimbursement, and marketing [4] Product Indications - NEXLIZET and NEXLETOL are indicated for reducing LDL-C cholesterol and the risk of cardiovascular disease in adults who cannot take statin therapy, as well as for adults with primary hyperlipidemia [6][8] Company Background - Esperion Therapeutics is focused on developing non-statin medications for patients at risk of cardiovascular disease, supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients [17][18] - CSL Seqirus is a major player in the influenza vaccine market and is committed to providing innovative pharmaceuticals for various health conditions, including cardiovascular disease [15][16]

Core Viewpoint - Esperion Therapeutics (ESPR) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with a consensus outlook suggesting a quarterly loss of $0.14 per share, reflecting a 72% improvement from the previous year, and revenues expected to reach $70.01 million, marking a 117.1% increase from the same quarter last year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for March 4, and the stock may experience upward movement if the reported figures exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Esperion is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -8.70%, suggesting a bearish outlook from analysts [10]. - The stock currently holds a Zacks Rank of 4, complicating predictions of an earnings beat [11]. Historical Performance - In the last reported quarter, Esperion was expected to post a loss of $0.14 per share but actually reported a loss of $0.15, resulting in a surprise of -7.14% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [13]. Industry Comparison - Amneal Pharmaceuticals (AMRX), another player in the Zacks Medical - Drugs industry, is expected to report earnings of $0.15 per share, reflecting a year-over-year change of +7.1%, with revenues projected at $707.4 million, up 14.7% from the previous year [17]. - Amneal's consensus EPS estimate has remained unchanged, but a higher Most Accurate Estimate has resulted in an Earnings ESP of 2.27%, indicating a likelihood of beating the consensus EPS estimate [18].

Company Overview - Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing new medicines for unmet patient needs, particularly in cardiovascular disease [3] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for patients with elevated low-density lipoprotein cholesterol (LDL-C) [3] - Esperion's medications are supported by the CLEAR Cardiovascular Outcomes Trial, which involved nearly 14,000 patients [3] Financial Reporting - Esperion will report its third quarter 2024 financial results on March 4, 2025, before the market opens [1] - Following the financial results release, management will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates [1] Business Development - The company is advancing its next-generation program focused on developing ATP citrate lyase inhibitors (ACLYi), leveraging new insights into drug design [3] - Esperion is evolving into a leading global biopharmaceutical company through commercial execution, international partnerships, and collaborations [4]

Group 1 - Esperion will host a virtual key opinion leader (KOL) event to discuss the real-world use of its medications NEXLETOL and NEXLIZET for LDL-Cholesterol management [1] - The event will feature LeAnne Bloedon and Dr. Patrick Moriarty, highlighting the ongoing unmet need in LDL-Cholesterol management to prevent cardiovascular disease [1] - Registration for the KOL webinar is available, and a live audio webcast will be accessible on Esperion's website [1] Group 2 - Esperion Therapeutics is a commercial stage biopharmaceutical company focused on developing new medicines for patients at risk of cardiovascular disease with elevated LDL-C [2] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for this patient group, supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial [2] - Esperion is advancing its next-generation program focused on ATP citrate lyase inhibitors (ACLYi), enabling rational drug design for potent and specific inhibitors [2] Group 3 - Esperion is evolving into a leading global biopharmaceutical company through commercial execution, international partnerships, and advancements in its pre-clinical pipeline [3]

Core Viewpoint - Esperion has successfully closed a series of financing transactions, including a $150 million senior secured term loan and a new $100 million convertible note, aimed at repaying a significant portion of its existing $265 million convertible debt [1][2]. Financing Transactions - The financing includes a $150 million senior secured term loan led by Athyrium Capital Management and HealthCare Royalty, which will be used to repay $210 million of existing convertible debt [1][3]. - The new $100 million convertible notes will be issued to accredited investors, with proceeds also allocated for operational cash [1][5]. Debt Restructuring - The company has restructured 80% of its existing debt, extending the maturity date by five years or more, which enhances its financial flexibility [2]. - The loan will bear an interest rate of 9.75% if paid in cash and 11.75% if paid in-kind [3]. Investment Confidence - Athyrium Capital Management expressed confidence in Esperion's strategy and its potential for long-term success in developing innovative therapies for cardiovascular diseases [4][18]. Product Information - Esperion's products, NEXLETOL and NEXLIZET, are indicated for reducing the risk of cardiovascular events in patients unable to take statin therapy and for lowering LDL-C levels in adults with primary hyperlipidemia [6].

Core Viewpoint - Esperion has entered into privately negotiated exchange and subscription agreements to issue $100 million of new convertible senior subordinated notes, replacing existing notes due in 2025 with new notes due in 2030 [1][2]. Group 1: Exchange and Subscription Transactions - The company will issue approximately $57.5 million in new notes and $153.4 million in cash in exchange for approximately $210.1 million of existing 2025 notes, along with an additional $42.5 million in new notes for cash [1][3]. - The transactions are expected to close on or about December 17, 2024, subject to customary closing conditions [2]. Group 2: Financial Details and Use of Proceeds - Esperion will not receive cash proceeds from the exchange transactions but expects to receive approximately $42.5 million from the subscription transactions, which will be used for general corporate purposes [3]. - The new notes will have a semi-annual interest rate of 5.75% and will mature on June 15, 2030, with an initial conversion rate of 326.7974 shares per $1,000 principal amount [4]. Group 3: Redemption and Repurchase Rights - The new notes can be redeemed by the company starting December 20, 2027, under certain conditions, with the redemption price equaling the principal amount plus accrued interest [5]. - In the event of a fundamental change, holders may require the company to repurchase their notes at the principal amount plus accrued interest [6]. Group 4: Regulatory and Placement Information - The new notes will be issued only to accredited institutional investors and have not been registered under the Securities Act [7]. - The exchange transactions will be partially funded by a new $150 million senior secured term loan credit facility with Athyrium Capital Management [8].

Esperion Therapeutics, Inc. (ESPR) announced that it has filed new drug submissions (NDSs) in Canada to seek approval for its once-daily, oral non-statin drugs Nexletol (bempedoic acid) and Nexlizet as a treatment to reduce low-density lipoprotein cholesterol or LDL-C (bad cholesterol) and cardiovascular risk.Nexlizet is a combination of bempedoic acid and ezetimibe.Shares of the company were up 10.7% on Dec. 2 following the announcement of the news.ESPR stock has increased 3.6% so far this year against the ...

I maintain my buy rating on Esperion Therapeutics, Inc.(NASDAQ: ESPR ) given its strong Q3 2024 financial performance, which is a testament to the success of its unique value proposition discussed in my previousI am an experienced financial analyst and a former writer for Fade The Market on Seeking Alpha, with a passion for numbers and a knack for unraveling complex financial data. Armed with a strong financial modeling and data analysis background, I thrive on providing accurate insights and recommendation ...